ADC Manufacturing Strategy & CMC
Commercial manufacturing strategy, CMC readiness, bioconjugation, and process development.
Program faculty
A curated faculty of global pharmaceutical executives, biotechnology innovators, CDMO leaders, regulators, and manufacturing experts shaping the future of ADC manufacturing and commercialization.
First faculty announcements coming soon
2027 Faculty
Speaker invitations and submissions are currently under review. Confirmed faculty profiles, companies, and session titles will be published here in the first announcement wave.
We are curating a balanced program of drug developers, CDMOs, technical specialists, and regulatory leaders.
Expertise represented
Commercial manufacturing strategy, CMC readiness, bioconjugation, and process development.
High-containment and aseptic manufacturing, Annex 1, fill-finish, and technology transfer.
Global supply chain, cold chain, commercial scale-up, and launch readiness.
Global regulatory strategy, quality systems, digital and AI-enabled manufacturing.
Who we invite to speak
Our program committee curates speakers from the organizations defining how ADCs are manufactured, regulated, and brought to market.
Call for speakers
We welcome evidence-led contributions from biopharma developers, manufacturers, regulators, and supply-chain leaders. The program prioritizes operational lessons and audience takeaways; commercial sales presentations are not accepted.
ADC NEXUS 2027
Tell the program team about your expertise and proposed contribution. Required fields are marked with an asterisk.